NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 65 resultados LastUpdate Última actualización 22/09/2017 [14:19:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


THERAPEUTIC AGENT FOR PLASMA CELL NEOPLASM

NºPublicación: WO2017159835A1 21/09/2017

Solicitante:
UNIV SAPPORO MEDICAL [JP]

Resumen de: WO2017159835A1

The purpose of the present invention is to provide: a medicinal composition for treating plasma cell neoplasm, in particular, multiple myeloma; a method for treating plasma cell neoplasm, said method comprising administering the aforesaid medicinal composition; a method for inducing apoptosis of a myeloma cell, said method comprising bringing a DPP-8 inhibitor into contact with the myeloma cell; etc. The aforesaid purpose has been achieved by a medicinal composition that comprises at least one kind of dipeptidyl peptidase (DPP)-8 activity inhibitor.



traducir


 

METHOD FOR IDENTIFYING CLINICAL TRIAL RESPONDERS FROM A PLACEBO GROUP IN MAJOR DEPRESSION

NºPublicación: WO2017161289A1 21/09/2017

Solicitante:
TAKEDA PHARMACEUTICALS CO [JP]
FFRENCH-MULLEN JARLATH [US]

Resumen de: WO2017161289A1

The present invention provides methods and kits for identifying clinical trial responders from a placebo group in clinical trials for treating depression and/or major depressive disorder (MDD). The present invention further provides methods and kits for treating depression and/or MDD in an individual, and for identifying the likelihood that an individual suffering from depression and/or MDD will respond favorably to administration of a placebo and/or experience an enhanced placebo effect when administered a placebo. These methods and kits comprise determining the presence of polymorphisms in the Brain-Derived Neurotrophic Factor gene (BDNF), the B-Cell CLL/Lymphoma 2 gene (BCL2), and/or intergenic regions in an individual.



traducir


 

SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE

NºPublicación: WO2017161028A1 21/09/2017

Solicitante:
KURA ONCOLOGY INC [US]
UNIV MICHIGAN REGENTS [US]

Resumen de: WO2017161028A1

The present disclosure provides methods of inhibiting the interaction of menin with MLLl, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLLl, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.



traducir


 

PHARMACEUTICAL COMPOSITION OF NILOTINIB

NºPublicación: WO2017158625A1 21/09/2017

Solicitante:
SUN PHARMACEUTICAL IND LTD [IN]

Resumen de: WO2017158625A1

A method of treating leukaemia comprising orally administering to a patient in need thereof reduced daily doses of nilotinib of 100 mg to 600 mg, wherein the nilotinib is administered in a dosage form having a composition comprising nilotinib butanedisulphonate (2:1) or nilotinib butanedisulphonate (1:1).



traducir


 

TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO CLEAVABLE LINKING MOIETIES

NºPublicación: WO2017161288A1 21/09/2017

Solicitante:
UNIV RUTGERS [US]
UNIV GEORGETOWN [US]

Resumen de: WO2017161288A1

The present invention relates to anti-matriptase antibodies and immunoconjugates of anti- matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of an anti-matriptase antibody or immunoconjugates of an anti-matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.



traducir


 

COMPOSITIONS AND METHODS FOR TREATING CANCERS

NºPublicación: WO2017160761A2 21/09/2017

Solicitante:
KIROMIC INC [US]

Resumen de: WO2017160761A2

Compositions and methods for treating solid and hematological cancers, including Acute Myeloid Leukemia (AML), are provided herein. The methods include administering truncated, dominant-negative, forms of Galectin-3.



traducir


 

BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE

NºPublicación: WO2017161002A1 21/09/2017

Solicitante:
KURA ONCOLOGY INC [US]
UNIV MICHIGAN REGENTS [US]

Resumen de: WO2017161002A1

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.



traducir


 

PD1 AND PDL-1 EXPRESSION DURING PROGRESSION FROM MYELODYSPLASTIC SYNDROME TO ACUTE MYELOGENOUS LEUKEMIA

NºPublicación: WO2017161154A2 21/09/2017

Solicitante:
H LEE MOFFITT CANCER CENTER & RES INST INC [US]

Resumen de: WO2017161154A2

The present disclosure relates to a method for diagnosing in a subject the progression from myelodysplastic syndrome (MDS) to acute myelogenous leukemia (AML). Also disclosed are methods of treating AML in a subject diagnosed by the disclosed methods.



traducir


 

HISTONE DEMETHYLASE INHIBITORS

NºPublicación: WO2017161033A1 21/09/2017

Solicitante:
CELGENE QUANTICEL RES INC [US]

Resumen de: WO2017161033A1

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as pancreatic cancer, prostate cancer, breast cancer, bladder cancer, lung cancer, gastric cancer, leukemia and/or melanoma and the like.



traducir


 

INTRACELLULAR OSTEOPONTIN REGULATES THE LINEAGE COMMITMENT OF LYMPHOID SUBSETS

NºPublicación: US2017269076A1 21/09/2017

Solicitante:
DANA-FARBER CANCER INST INC [US]

Resumen de: US2017269076A1

Methods for diagnosing and prognosing autoimmune diseases and T cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (OPN-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor Bcl6, which is involved in T cell activation/differentiation. Other aspects of the disclosure provide methods for enhancing adoptive T cell transfer.



traducir


 

PROGNOSTIC METHODS AND SYSTEMS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

NºPublicación: US2017268070A1 21/09/2017

Solicitante:
MOR RES APPLICATIONS LTD [IL]

Resumen de: US2017268070A1

Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL), and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider, and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.



traducir


 

PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING

NºPublicación: US2017266285A1 21/09/2017

Solicitante:
VISION GLOBAL HOLDINGS LTD [HK]

Resumen de: US2017266285A1

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.



traducir


 

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

NºPublicación: US2017266193A1 21/09/2017

Solicitante:
AGIOS PHARMACEUTICALS INC [US]

Resumen de: US2017266193A1

Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL).



traducir


 

USE OF ETONOGESTREL IN PREPARATION OF ANTI-B CELL LYMPHOMA PRODUCTS

NºPublicación: WO2017156967A1 21/09/2017

Solicitante:
UNIV SHANGHAI JIAOTONG [CN]

Resumen de: WO2017156967A1

A use of etonogestrel in the preparation of anti-B cell lymphoma products.



traducir


 

ANTI-ROR1 ANTIBODIES

NºPublicación: EP3219731A1 20/09/2017

Solicitante:
OXFORD BIOTHERAPEUTICS LTD [GB]

Resumen de: EP3219731A1

The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor ROR1. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia and colon cancer.



traducir


 

DEEP SEQUENCING OF PERIPHERAL BLOOD PLASMA DNA AS A RELIABLE TEST FOR CONFIRMING THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME

NºPublicación: EP3218520A1 20/09/2017

Solicitante:
NEOGENOMICS LABORATORIES INC [US]

Resumen de: US2016130648A1

Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.



traducir


 

METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH A COMBINATION THERAPY USING LENALIDOMIDE AND AZACITIDINE

NºPublicación: EP3219317A1 20/09/2017

Solicitante:
CELGENE CORP [US]

Resumen de: EP3219317A1

The application relates to a compound being 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or a pharmaceutically acceptable salt thereof for use in a method of treating a myelodysplastic syndrome, wherein the method further comprises administering to a patient having a myelodysplastic syndrom 5-azacytidine, and wherein the myelodysplastic syndrome has a score of 1.0 or lower in international prognostic scoring system (IPSS).



traducir


 

METHODS OF TREATING ATOPIC DERMATITIS WITH IL-31 MONOCLONAL ANTIBODIES

NºPublicación: US2017260267A1 14/09/2017

Solicitante:
ZYMOGENETICS INC [US]

Resumen de: US2017260267A1

The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.



traducir


 

MEDIUM SUPPLEMENT TO INCREASE THE EFFICIENCY OF OOCYTE MATURATION AND EMBRYO CULTURE IN VITRO

NºPublicación: US2017258495A1 14/09/2017

Solicitante:
YUAN YE [US]
SPATE LEE D [US]
PRATHER RANDALL S [US]
ROBERTS R MICHAEL [US]
THE CURATORS OF THE UNIV OF MISSOURI [US]

Resumen de: US2017258495A1

The present invention provides a novel oocyte maturation medium or/and embryo culture medium with a chemically defined supplement to produce matured oocytes at high efficiency. The inventive medium or supplement comprises three growth factors, namely, fibroblast growth factor 2 (FGF2), leukemia inhibitory factor (LIF), and insulin-like growth factor 1 (IGF-1) in a synergistic combination. Methods for oocyte and embryo culture are also provided.



traducir


 

Antagonism of the VIP Signaling Pathway

NºPublicación: US2017258904A1 14/09/2017

Solicitante:
UNIV EMORY [US]

Resumen de: US2017258904A1

Inhibition of the VIP signaling pathway with VIP antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a VIP antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma. In certain embodiments, the cell is a blood cell, bone marrow cell, leukocyte, T-cell, natural killer cell, a hematopoietic stem cell, a G-CSF mobilized or non-mobilized blood mononuclear cell.



traducir


 

Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor

NºPublicación: US2017258729A1 14/09/2017

Solicitante:
PHARMACYCLICS LLC [US]

Resumen de: US2017258729A1

Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.



traducir


 

COMPOSITIONS FOR EXPANDING REGULATORY T CELLS (TREG), AND TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES AND CONDITIONS

NºPublicación: US2017260236A1 14/09/2017

Solicitante:
UNIV CALIFORNIA [US]

Resumen de: US2017260236A1

Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory T cells (Treg) populations; for treating or ameliorating a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and methods for making and using them. Provided are immunotherapies for promoting expansion of natural, Treg to establish, or re-establish, vascular homeostasis; or, for ameliorating: a disease or condition associated with an autoimmune disease or condition; an immune-mediated vascular disorder; a disease or condition treated with intravenous immunoglobulin (WIG) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune inflammatory vasculitis; a T cell mediated pediatric vasculitis; Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; preventing miscarriage in autoimmune women; rheumatoid arthritis or Juvenile Idiopathic Arthritis; a neoplastic hematological disorder, or a leukemia.



traducir


 

METHODS FOR TREATING CANCERS

NºPublicación: US2017258804A1 14/09/2017

Solicitante:
GILEAD SCIENCES INC [US]

Resumen de: US2017258804A1

or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma.



traducir


 

Treatment of Acute Lymphoblastic Leukemia

NºPublicación: AU2017219083A1 14/09/2017

Solicitante:
AMGEN RES (MUNICH) GMBH

Resumen de: AU2017219083A1

The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to an adult 5 patient in the need thereof.



traducir


 

INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA

Nº publicación: WO2017156489A1 14/09/2017

Solicitante:
UNIV LELAND STANFORD JUNIOR [US]

Resumen de: WO2017156489A1

Compounds and methods are provided for inhibiting a CREB-CBP protein-protein interaction in a sample. In some cases, the method includes modulating transcription of CREB in a cell that overexpresses CREB. Also provided are methods of inhibiting the proliferation of a cancer cell. The subject CREB transcription inhibitor compounds include a substituted salicylamide or a prodrug thereof. Methods of alleviating symptoms associated with cancer (e.g., Acute Myeloid Leukemia (AML) or Acute Lymphomblastic Leukemia (ALL)) in a subject in need thereof are also provided. Pharmaceutical compositions including the subject compounds find use in treating cancer. The subject compounds may be formulated or provided to a subject in combination with a second agent, e.g. an anticancer agent.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver